Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below

Mechanisms of cisplatin ototoxicity and progress in otoprotection.

Author information

  • Division of Otolaryngology, Department of Surgery, Southern Illinois University, School of Medicine, Springfield, Illinois 62794-9653, USA. lrybak@siumed.edu



This review presents exciting new data published in the past year that help to elucidate the mechanisms of cisplatin ototoxicity. Recent research findings on otoprotection could lead to the development of novel protective agents. Cisplatin ototoxicity is a frequent and serious problem in patients. Strategies to ameliorate ototoxicity without interfering with the desired therapeutic effects are urgently needed.


Cisplatin ototoxicity appears to involve the production of reactive oxygen species in target tissues in the inner ear by activating an enzyme unique to the cochlea. This leads to a cascade resulting in oxidation of lipids and cell death. The upregulation of endogenous protective mechanisms in the cochlea or treatment with exogenous compounds reduces ototoxicity in cisplatin-treated animals. The only clinical trials reported to date with the putative protective agent, amifostine, have been disappointing.


The data summarized in this paper could lead to important clinical trials to determine whether the findings in experimental animals can translate into effective treatments to prevent cisplatin ototoxicity.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk